Molecule development begins with target identification and validation. A new drug starts as an idea or hypothesis based on
- Observations made during phenotypic drug discovery evaluations, or
- Direct identification of targets with affinity during target-based drug discovery processes
Both these approaches require comprehensive understanding of the biological and molecular pathways underlying disease.
See how our IncuCyte® Live-Cell Analysis and Intellicyt® iQue3 platforms can accelerate your mAb discovery workflow!
Challenges and Solutions for Developing New Monoclonal Antibodies
Unprecedented advances in medicine are delivering remarkable results for some patients. Recent approvals of CAR T therapies and new approaches in regenerative medicine, for example, exemplify Monoclonal antibodies (mAbs) used for immunotherapy stimulate the immune system to mount a response to target antigens. These powerful therapeutics are being used to...
Accelerating Nanobody Discovery Workflows with High-Throughput Flow Cytometry
In this webinar, Dr. Pieter Kennis discusses how nanobodies – small, single-domain antibody fragments that retain full antigen-binding capabilities and the properties of heavy-chain antibodies – and nanobody discovery and screening platforms exploit high-throughput flow cytometry to increase the throughput of nanobody screening campaigns.
IncuCyte® Live-Cell Analysis System
Don't miss crucial data by analyzing cells at pre-determined time points. Continuously interrogate dynamic changes in the same population of cells using imaged-based, real-time, live-cell analysis for relevant insight to cell- and treatment-specific responses – all from inside your incubator.
Advance therapeutic antibody discovery with multiplexed screening. The Intellicyt iQue3 offers high content, multi-factorial, and actionable results for more insight and better decisions.